IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0063571
(2013-10-25)
|
| 등록번호 |
US-9750636
(2017-09-05)
|
|
발명자
/ 주소 |
- Rubin, Anne Brody
- Alster, Yair
- Reich, Cary J.
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
|
| 인용정보 |
피인용 횟수 :
0 인용 특허 :
116 |
초록
▼
Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through
Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.
대표청구항
▼
1. An ocular device configured to be positioned on a surface of the eye at least partially underneath at least one of the upper and lower eyelids and outside a cornea of the eye for delivering at least one therapeutic agent to an eye for an extended period of time, the device comprising: a thin, elo
1. An ocular device configured to be positioned on a surface of the eye at least partially underneath at least one of the upper and lower eyelids and outside a cornea of the eye for delivering at least one therapeutic agent to an eye for an extended period of time, the device comprising: a thin, elongated filamentous first structure formed of a first material;a second structure formed of a second material having a tubular structure such that the first structure extends through a lumen of the tubular structure, wherein the second material is different from the first material; andat least one therapeutic agent dispersed within at least one of the first material of the first structure or the second material of the second structure,wherein the second structure has at least two grooves formed in an outer surface of the tubular structure providing a cross-sectional shape to the tubular structure along a cross-section taken across the lumen from an anterior surface to a posterior surface of the tubular structure, wherein the outer surface is configured to contact a surface of the eye upon positioning the ocular device outside the cornea. 2. An ocular device as in claim 1, wherein the cross-sectional shape is selected from the group consisting of figure-eight or gear-shaped. 3. An ocular device as in claim 1, wherein the first structure is thermally fused into a ring shape after being threaded through the lumen of the second structure. 4. An ocular device as in claim 1, wherein the second structure formed of a second material is molded into two or more tubular structures, wherein each of the two or more tubular structures has a lumen through which the first structure extends. 5. An ocular device as in claim 4, wherein a first of the two or more tubular structures is formulated to release the at least one therapeutic agent and wherein a second of the two or more tubular structures is formulated to release the at least one therapeutic agent or at least a second therapeutic agent dispersed within the second material of the second structure, wherein the at least one therapeutic agent and the at least a second therapeutic agent are the same or different therapeutic agents. 6. An ocular device as in claim 1, wherein the first material is non-erodible and has a stiffness that conforms into a second, different shape after positioning the ocular device on the surface of the eye, and wherein upon being removed from the eye, the ocular device retains the second shape or changes to a third shape, wherein the third shape is different from both the first shape and the second shape. 7. An ocular device as in claim 6, wherein the second shape is a shape of at least a portion of the conjunctiva of the eye. 8. An ocular device as in claim 6, wherein the second shape is a shape of at least a portion of the bony orbit of the eye. 9. An ocular device as in claim 7, wherein the second shape is a shape of at least a portion of bony orbit of the eye. 10. An ocular device as in claim 6, wherein the ocular device resists deflection away from the second shape upon being removed from the eye. 11. An ocular device as in claim 6, wherein the first shape is an annular shape positioned substantially within a first plane and the second and third shapes are positioned at least partially outside of the first plane. 12. An ocular device as in claim 6, wherein the second shape corresponds to a surface of a saddle. 13. An ocular device as in claim 6, wherein the second shape has an outer contour that corresponds to an outer contour of a saddle. 14. An ocular device as in claim 6, wherein the ocular device changes from the first shape to the second shape over a period of about 20 minutes to about 24 hours. 15. An ocular device as in claim 1, wherein the first material comprises a material configured to repeatedly become plastic upon exposure to heat, liquid, or pressure. 16. An ocular device as in claim 1, wherein the first material comprises a thermoplastic material. 17. An ocular device as in claim 16, wherein the first material comprises polypropylene. 18. An ocular device as in claim 1, wherein the second material comprises a silicone material. 19. An ocular device as in claim 18, wherein only the second material comprises the at least one therapeutic agent. 20. An ocular device as in claim 1, wherein the at least one therapeutic agent comprises an agent selected from the group consisting of bimatoprost, travoprost, latanoprost, tafluprost, NSAID, steroid, antihistamine, carbonic anhydrase inhibitor (CAI), dorzolamide, cyclosporine, antibiotic, doxycycline, tetracycline, azithromycin, fatty acid, long chain fatty acid, fatty alcohol, cetyl alcohol, stearyl alcohol, non-penetrating steroid, free acid of steroid, lipid, ketorolac, silicone oil, olopatadine, prostaglandin, prostaglandin analog, prostamide, small-molecule integrin antagonist, lifitegrast, loteprednol, and fluoromethalone or a combination thereof. 21. An ocular device as in claim 1, wherein the at least one therapeutic agent comprises a prostaglandin analogue. 22. An ocular device as in claim 21, wherein the prostaglandin analogue comprises at least one of bimatoprost, latanoprost, travoprost, and tafluprost. 23. An ocular device as in claim 1, wherein the at least one therapeutic agent is for lowering the intraocular pressure of the eye. 24. An ocular device as in claim 1, wherein the at least one therapeutic agent is for treating dry eye. 25. An ocular device as in claim 24, wherein the at least one therapeutic agent comprises at least one of cyclosporine, steroid, loteprednol, fluoromethalone, non-penetrating steroid, free acid of steroid, non-steroidal anti-inflammatory, ketorolac, small-molecule integrin antagonist, lifitegrast, doxycycline, azithromycin, lipid, fatty alcohol, cetyl alcohol, stearyl alcohol, fatty acid, long chain fatty acid, oil, or silicone oil. 26. An ocular device as in claim 1, wherein the at least one therapeutic agent comprises a steroid. 27. An ocular device as in claim 26, wherein the steroid comprises at least one of loteprednol or fluoromethalone. 28. An ocular device as in claim 1, wherein the cross-sectional shape of the tubular structure increases a surface area of the second structure and an elution rate of the at least one therapeutic agent from the device. 29. An ocular device as in claim 1, wherein the tubular structure has a maximum cross-sectional diameter and a surface area exposed to the eye, wherein the maximum cross-sectional diameter is between 0.5 mm and 1.5 mm. 30. An ocular device as in claim 29, wherein the cross-sectional shape varies along a circumferential length of the device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.